FDA accepts premarket approval application for DE-128 microshunt

Posted on

The U.S. Food and Drug Administration has accepted the premarket approval (PMA) application for DE-128 (MicroShunt) for review, according to a press release from Santen Pharmaceutical Co.

The microshunt is an investigational surgical glaucoma implant designed to reduce intraocular pressure (IOP) in patients with primary open-angle glaucoma (POAG) whose IOP is not controlled when using maximum tolerated glaucoma medications.

Read the full press release here.  

Source: Santen Pharmaceutical Co., Ltd.

Related Articles
IOP outcomes after laser trabeculoplasty in eyes with prior Kahook Dual Blade goniotomy limited
Jul 28, 2021
Hydrus microstent reduces IOP, medication burden
Jul 26, 2021
IOP, gel microstents complications leading cause of reoperation after MIGS
Jul 23, 2021